Targeting NLRP3 signaling with a novel sulfonylurea compound for the treatment of vascular cognitive impairment and dementia
2024

New Drug AMS-17 Helps Treat Vascular Dementia in Mice

Sample size: 30 publication 10 minutes Evidence: moderate

Author Information

Author(s): Akif Adnan, My Nguyen Thi Thanh, Liu Langni, Xu Xiaotian, Kulkarni Amol, Jiang Jianxiong, Zhang Yang, Hao Jiukuan

Primary Institution: University of Houston

Hypothesis

Can AMS-17 improve cognitive function and reduce neuroinflammation in a mouse model of vascular dementia?

Conclusion

AMS-17 treatment improved cognitive function and reduced neurodegeneration in mice with vascular dementia.

Supporting Evidence

  • AMS-17 treatment improved cognitive function in the Y-maze and Morris water maze tests.
  • AMS-17 reduced neurodegeneration as indicated by decreased FJC-positive cells.
  • AMS-17 enhanced myelin integrity as shown by increased MBP levels.
  • AMS-17 treatment restored blood-brain barrier integrity by increasing tight junction protein expression.

Takeaway

Researchers found that a new drug called AMS-17 can help mice with memory problems caused by blood flow issues in the brain. It makes their brains healthier and helps them remember better.

Methodology

The study used a mouse model of vascular dementia and assessed cognitive function through behavioral tests and analyzed brain samples for neurodegeneration and inflammation markers.

Potential Biases

Potential bias in animal model selection and treatment administration.

Limitations

The study was conducted in mice, and further research is needed to confirm the effects in humans.

Participant Demographics

10-month-old male C57BL/6J mice.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.21203/rs.3.rs-5611378

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication